home

Sanofi opens UK bioscience partnering office

R&Dpmlive2016-04-15 10:56 Read   76

Sanofi has opened an office in Stevenage that will try to foster partnerships with life science research groups in the UK.

Priority review for Keytruda in head and neck cancer

R&Dpmlive2016-04-15 10:38 Read   150

The FDA has started a priority review of Merck & Co's PD-1 inhibitor Keytruda in head and neck cancer, raising the prospect of a third indication for the fast-growing immuno-oncology drug.

Health Tip: Are Your Feet Getting Enough Blood?

Healthdrugs2016-04-15 10:21 Read   92

When blood circulation to your feet is poor, your feet may be at real risk of damage.

Billion-dollar T-cell biotech Bavarian Nordic abandons $86 million US listing

EVENTSrenaissancecapital2016-04-15 10:15 Read   89

Bavarian Nordic, which is developing vaccines that stimulate a T-cell response to fight infectious diseases and cancers, withdrew its plans for an initial public offering on Wednesday, citing market conditions. It originally filed in January 2016 with a proposed deal size of $86 million.

Bristol-Myers expands I/O hub, may hire up to 150 more for discovery team

R&Dfiercebiotech2016-04-15 10:12 Read   99

Bristol-Myers Squibb is once again growing its footprint in the fast-growing immuno-oncology R&D world. The biopharma company inked a lease on the third and final facility BioMed Realty owns at Woodside Technology Park in Redwood City, CA, opening the door to an expansion of its biologics discovery team, set to grow from the 250 now employed at the hub to as many as 400 with the add-on.

AmpliPhi Biosciences Terminates Collaboration Agreement with Intrexon

R&DAmpliPhi2016-04-15 10:06 Read   87

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to Intrexon to cancel the Exclusive Channel Collaboration (ECC) with Intrexon.

Merck Provides Update on Filing Plans for Omarigliptin, an Investigational DPP-4 Inhibitor for Type 2 Diabetes

Trendmercknewsroom2016-04-15 09:47 Read   380

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company will not proceed with submitting marketing applications for omarigliptin, an investigational, once-weekly DPP-4 inhibitor, in the United States or Europe.

Cydan Development Announces Formation of Imara Inc. with $31M Series A Funding to Develop Therapeutic for Sickle Cell Disease

EVENTSbusinesswire2016-04-15 09:39 Read   63

Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc. This is the second orphan drug company launched by Cydan since 2015. Imara will develop IMR-687, a disease-modifying therapeutic selected specifically for the treatment of sickle cell disease and other hemoglobinopathies. IMR-687 was discovered by H. Lundbeck A/S.

Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

Trendbusinesswire2016-04-15 09:32 Read   77

“Following an extensive review of strategic alternatives, Synta’s Board of Directors believes that a merger with Madrigal Pharmaceuticals offers shareholders the most compelling opportunity for enhancing long-term value”

Contract Research Organization Participation in Clinical Trial Design Projected to Increase 206 Percent by 2020, According to Cutting Edge Information

EVENTSmarketwired2016-04-15 09:28 Read   96

Pharmaceutical and medical device teams plan to increasingly involve contract research organizations (CROs) in their clinical trial planning processes.

Redx Pharma Plc set for new HQ at Alderley Park

EVENTSredxpharma2016-04-15 09:21 Read   89

Redx Pharma Plc is to establish new headquarters at Alderley Park, Cheshire, creating a 74,000 sq. ft. state-of-the-art drug development facility that brings together its three subsidiary businesses onto one site.

Nabriva Initiates Second Phase 3 Clinical Trial of Lefamulin (“LEAP 2”) in Patients with Community-Acquired Bacterial Pneumonia (CABP)

Trendnabriva2016-04-15 09:15 Read   102

Nabriva Therapeutics AG today announced the initiation of the second of two Phase 3 multinational pivotal trials evaluating the safety and efficacy of Nabriva’s lead product candidate, lefamulin, for the treatment of adults with community-acquired bacterial pneumonia (CABP).